BRIEF-Mylan invalidates two of Teva's Copaxone patents

* Mylan invalidates two of Teva's Copaxone 40 mg/ml patents via U.S. Patent and Trademark Office's Inter Partes Review proceeding
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.